Table 1 The variables of training and validation cohort
|  | Patients (n = 325) | Training group (n = 227) | Validation group (n = 98) | P |
|---|---|---|---|---|
Age, monthsb | 5(2–10) | 5(2–10) | 5(3–9.3) | 0.936 |
Sex, male/female | 206/119 | 146/81 | 60/38 | 0.595 |
weight at admission, kgb | 7.8(6.3–9.5) | 7.7(6.2–9.6) | 7.8(6.5–9.4) | 0.836 |
Region, rural/urban | 110/215 | 79/148 | 31/67 | 0.580 |
preterm birth, n(%) | 36(11.1%) | 27(11.9%) | 9(9.2%) | 0.475 |
cesarean section, n(%) | 171(52.6%) | 121(53.3%) | 50(51%) | 0.705 |
history of birth asphyxia, n(%) | 6(1.8%) | 5(2.2%) | 1(1%) | 0.467 |
birth weight, kgb | 3.3(3.0–3.6) | 3.3(3.0–3.6) | 3.3(2.9–3.7) | 0.664 |
non-breastfeeding, n(%) | 173(53.2%) | 124(54.6%) | 49(50%) | 0.443 |
underlying diseases, n(%) | 16(4.9%) | 12(5.3%) | 4(4.1%) | 0.645 |
history of wheezing, n(%) | 20(6.2%) | 16(7.0%) | 4(4.1%) | 0.307 |
history of eczema, n(%) | 143(44%) | 106(46.7%) | 37(37.8%) | 0.136 |
Fever, n(%) | 178(54.8%) | 128(56.4%) | 50(51%) | 0.372 |
Length of cough, daysb | 4(3–6) | 4(3–6) | 4(3–8) | 0.681 |
Length of wheezing, daysb | 1(0–3) | 1(0–3) | 2(0–4) | 0.017 |
Outpatient use of antibiotics, n(%) | 247(76%) | 168(74%) | 79(80.6%) | 0.201 |
Outpatient use of glucocorticoids, n(%) | 86(26.5%) | 57(25.1%) | 29(29.6%) | 0.401 |
Breath rateb | 45(40–51) | 45(40–51) | 44(40–51.5) | 0.845 |
Three concave signs, n(%) | 98(30.2%) | 66(29.1%) | 32(32.7%) | 0.579 |
Abnormal lung auscultation, n(%) | 322(99.1%) | 224(98.7%) | 98(100%) | 0.253 |
Abnormal radiological findings, n(%) | 198(60.9%) | 141(62.1%) | 57(58.2%) | 0.503 |
Length of stay, daysb | 6(5–7) | 6(5–7) | 5(4–7) | 0.303 |
WBC, × 109/La | 8.8 ± 3.3 | 8.6 ± 3.3 | 9.3 ± 3.2 | 0.105 |
N%a | 32.2 ± 15.4 | 33.1 ± 15.6 | 29.9 ± 14.8 | 0.078 |
L%a | 57.2 ± 15.1 | 56.1 ± 15.1 | 59.5 ± 14.8 | 0.063 |
E%b | 0.0(0.0–2.0) | 0.0(0.0–2.0) | 0.0(0.0–2.0) | 0.540 |
Hb, g/Lb | 115(106–121) | 114(105–121) | 111(104.5–119) | 0.166 |
CRP, mg/Lb | 2.5(2.5–2.7) | 2.5(2.5–3.0) | 2.5(2.5–2.5) | 0.384 |
PCT, ng/mlb | 0.07(0.05–0.10) | 0.07(0.05–0.10) | 0.07(0.05–0.10) | 0.265 |
IL-6, pg/mlb | 7.6(4.4–13.4) | 7.7(4.4–12.4) | 7.1(4.2–15.7) | 0.985 |
La, mol/Lb | 3.2(2.6–4.0) | 3.2(2.6–3.9) | 3.3(2.5–4.3) | 0.786 |
AST, U/Lb | 44(36–59) | 43.0(34.0–58) | 47(38.8–63) | 0.038 |
ALT, U/Lb | 22(17.0–34.0) | 22.0(16–32) | 24.5(18.0–37.3) | 0.057 |
CK, U/Lb | 103.0(74–146) | 104(78–146) | 100.5(69.5–146) | 0.543 |
CKMB, Ub/L | 12(7–23) | 12(7.0–23) | 12(7.0–24.3) | 0.663 |
LDH, U/Lb | 398((340.5–493.5) | 392(337–482) | 415.5(346.3–515) | 0.079 |
IgE, IU/Lb | 12.9(3.8–40.6) | 11.5(3.3–38.7) | 12.4(4.5–47.4) | 0.851 |